Chemotherapy News and Research

Latest Chemotherapy News and Research

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

PET allows survival predictions in sarcoma after initial cycle of neoadjuvant chemo

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

3 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

AngioDynamics presents NanoKnife System clinical study results at SSO 2012

AngioDynamics, a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced presentations on NanoKnife System clinical experience were given at the Society of Surgical Oncology (SSO) 2012 conference that took place March 21-24, 2012, in Orlando, Fla.

2 Apr 2012

Scientists use DNA sequencing to identify 'driver' mutations in cancer

Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.

2 Apr 2012

RT3D may boost effects of two standard chemotherapy drugs in head and neck cancer patients

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published today in Clinical Cancer Research.

2 Apr 2012

Survivin protein could be a useful tool in understanding pancreatic cancer

Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.

2 Apr 2012

Galeterone safe, effective for patients with CRPC

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

New paradigm for immunotherapy against cancer

Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

2 Apr 2012

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.

2 Apr 2012

Tokai Pharmaceuticals announces data from galeterone Phase 1 trial for CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study.

2 Apr 2012

$Pazopanib demonstrates clinically meaningful activity in patients with refractory urothelial cancer$

Pazopanib demonstrates clinically meaningful activity in patients with refractory urothelial cancer

The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy.

2 Apr 2012

New breast cancer gene mutation discovered

A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.

1 Apr 2012

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.

31 Mar 2012

Cancer patients with CDI may benefit from DIFICLIR drug

New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure, recurrence and sustained clinical cure.

31 Mar 2012

Study identifies key mechanism behind breast cancer metastasis

A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer metastasis and identifies new therapeutic targets for a lethal form of invasive breast cancer that is notoriously resistant to treatment.

30 Mar 2012

Scientists identify potential drug target for mixed lineage leukaemia

Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia - a cancer with limited treatment options and relatively poor survival, according to research published in Cancer Cell today.

30 Mar 2012

Study explains how rapamycin also causes insulin resistance

A Penn- and MIT-led team explained how rapamycin, a drug that extends mouse lifespan, also causes insulin resistance. The researchers showed in an animal model that they could, in principle, separate the effects, which depend on inhibiting two protein complexes, mTORC1 and mTORC2, respectively.

30 Mar 2012